Portmann-Baracco 2020: Antiviral and anti-inflammatory properties of ivermectin and its potential use in COVID-19

Ivermectin RxArchivos de Bronconeumologia, 56(12): 831-836.

This is a letter to the editor describing the experimental use of Ivermectin for Covid-19.

Ivermectin is a safe and well tolerated drug often used as a single dose for parasitosis. Thus, they used a single dose for 704 patients hospitalized with Covid-19 and compared them with 704 controls.  Those receiving ivermectin who were also on ventilators died less (1.3% vs 7.3% of controls) and overall mortality was also better (1.4% vs. 8.5% of controls). 

The authors recommend more studies to determine which type of dosing is best. Meanwhile, it is already known that this drug not only shows an anti-inflammatory effect at the systemic level, but also specifically in lung tissue, including the hyper-inflammatory state called the cytokine storm. 

Original language || English translation


This entry was posted in 2016-2020, Articles, COVID Medications, Ivermectin. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *